Investor Western Standard LLC
13D/G Filings

This page shows a list of all the recent 13D/G filings made by Western Standard LLC . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).

When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.

Date Form Target Prev
Shares
Current
Shares
Change
(Percent)
Ownership
(Percent)
Change
(Percent)
2025-02-14 13G/A FFBCW / First Financial Bancorp 779,740 917,940
2024-10-18 13G FFBCW / First Financial Bancorp 779,740
2024-04-05 13G/A ABIO / ARCA biopharma, Inc. 944,234 1,410,143
2023-12-13 13D/A MACK / Merrimack Pharmaceuticals, Inc. 1,991,108 2,220,058
2023-09-11 13G ABIO / ARCA biopharma, Inc. 944,234
2023-08-14 13D/A MACK / Merrimack Pharmaceuticals, Inc. 1,188,845 1,991,108
2023-02-15 13G/A OPNT / Opiant Pharmaceuticals Inc 382,573 424,080
2022-11-28 13G OPNT / Opiant Pharmaceuticals Inc 382,573
2021-08-03 13G MRLN / Marlin Business Services Corp 801,924
2020-12-03 13D/A MACK / Merrimack Pharmaceuticals, Inc. 1,046,628 1,188,845
2020-07-24 13D/A MACK / Merrimack Pharmaceuticals, Inc. 842,913 1,046,628
2019-09-30 13D/A MACK / Merrimack Pharmaceuticals, Inc. 842,913 842,913
2019-09-27 13D/A MACK / Merrimack Pharmaceuticals, Inc. 842,913 842,913
2019-09-19 13D MACK / Merrimack Pharmaceuticals, Inc. 842,913
2014-04-03 13G SYNM / Syntroleum Corp 504,845